Litcius/Paper detail

Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells

Benigno C. Valdez, Yang Li, David Murray, Yan Liu, Yago Nieto, Qaiser Bashir, Muzaffar H. Qazilbash, Börje S. Andersson

2020Experimental Hematology14 citationsDOIOpen Access PDF

Topics & Concepts

PanobinostatGemcitabineCancer researchMelphalanCarboplatinPharmacologyPI3K/AKT/mTOR pathwayChemistryHistone deacetylase inhibitorHistone deacetylaseApoptosisBiologyMedicineTransplantationCancerInternal medicineChemotherapyCisplatinBiochemistryHistoneGeneHistone Deacetylase Inhibitors ResearchMultiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors
Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells | Litcius